Press release: “A new study showing that the heavily advertised cholesterol drug Vytorin doesn’t work any better than a newly available generic drug in slowing artery-clogging calls into question who should be taking the most potent cholesterol drugs. “This study gives us another important piece of the puzzle in the treatment of high cholesterol and heart disease risk,” said Steven Findlay, managing editor of Consumer Reports Best Buy Drugs, a public information and education project of Consumers Union, publisher of Consumer Reports. “While the results are not conclusive, they should compel doctors and patients to ask just who should be taking the strongest cholesterol lowering drugs.”